益气养阴汤联合厄洛替尼对中晚期肺腺癌患者免疫功能的影响

Effect of Yiqi Yangyin Decoction Combined with Erlotinib on Immune Function in Patients with Moderate and Advanced Lung Adenocarcinoma

目的研究益气养阴汤联合厄洛替尼对中晚期肺腺癌患者免疫功能的影响。方法选取成都市第一人民医院2019年4月至2020年3月收治的56例中晚期肺腺癌患者,按照随机数字表法分为对照组和观察组,各28例。对照组患者给予厄洛替尼治疗,观察组患者则在此基础上联合益气养阴汤治疗,两组患者治疗周期均为2个月。比较两组患者临床疗效、气阴两虚证积分疗效;比较两组患者治疗前后免疫功能指标;比较两组患者不良反应发生情况。结果观察组患者临床总有效率、气阴两虚证积分疗效均高于对照组(均P<0.05);两组患者治疗后CD8^(+)百分比相比,差异无统计学意义(P>0.05);对照组患者治疗前后CD3^(+)、CD4^(+)、CD8^(+)百分比、CD4^(+)/CD8^(+)比值比较,差异均无统计学意义(均P>0.05);与治疗前比,治疗后观察组患者CD3^(+)、CD4^(+)百分比、CD4^(+)/CD8^(+)比值均升高,且观察组高于对照组(均P<0.05);观察组患者不良反应总发生率低于对照组(P<0.05)。结论中晚期肺腺癌患者应用益气养阴汤联合厄洛替尼治疗的临床疗效显著,可明显改善患者气阴两虚证积分疗效和免疫功能,且安全性较高。

Objective To study the effect of Yiqi Yangyin Decoction combined with erlotinib on the immune function of patients with moderate and advanced lung adenocarcinoma.Methods 56 patients with moderate and advanced lung adenocarcinoma admitted to Chengdu First People's Hospital from April 2019 to March 2020 were selected and divided into the control group and the observation group according to the random number table method,with 28 patients in each group.The control group was treated with erlotinib,and the observation group was treated with Yiqi Yangyin Decoction combined with erlotinib.The treatment period of both groups was 2 months.The clinical efficacy and the integral efficacy of Qi and Yin deficiency syndrome were compared between the two groups.The immune function indexes of the two groups were compared before and after treatment.The incidence of adverse reactions was compared between the two groups.Results The total clinical effective rate and the cumulative efficacy of Qi and Yin deficiency syndrome of the observation group were higher than those of the control group(all P<0.05);There was no significant difference in the percentage of CD8+between the two groups after treatment(P>0.05);There were no significant differences in the percentages of CD3^(+),CD4^(+),CD8^(+)and the ratio of CD4^(+)/CD8^(+)of the control group before and after treatment(all P>0.05);Compared with before treatment,after treatment the percentages of CD3^(+) and CD4^(+) and the ratio of CD4^(+)/CD8^(+)of the observation group significantly increased,and the observation group was significantly higher than the control group(all P<0.05);The total incidence of ADR of the observation group was lower than the control group(P<0.05).Conclusion Yiqi Yangyin Decoction combined with erlotinib has significant clinical efficacy in the treatment of middle and advanced lung adenocarcinoma,which can significantly improve the integral efficacy and immune function of patients with Qi and Yin deficiency syndrome,with high safety.